Emergent BioSolutions Inc. provides a variety of products and solutions that address public health threats, including manufacturing for the development of new vaccines. In April 2020, during the initial months of the COVID-19 pandemic, Emergent entered an agreement with J&J to provide its Bayview manufacturing facilities to support J&J’s goal of supplying one billion doses of a COVID-19 vaccine. Under the deal, valued at $135 million, Emergent would provide drug substance manufacturing services and reserve large-scale manufacturing capacity for J&J.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The Company is developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. In June 2020, Acadia submitted a supplemental New Drug Application ("sNDA") with the FDA to expand pimavanserin's label to include treatment for dementia-related psychosis.

Churchill Capital Corporation IV is a blank check company, also known as a special purpose acquisition company (“SPAC”).  On Monday, February 22, 2021, a merger agreement between Churchill Capital Corporation IV ("CCIV") and Lucid Motors was announced. CCIV’s and Lucid’s transaction equity value was estimated at $11.75 billion. Details of the merger disclosed that Lucid was projecting the production of only 557 vehicles in 2021, instead of the 6,000 it had allegedly been touting in the run-up to the merger announcement.

LifeMD, Inc. is a direct-to-patient telehealth company. It offers a telemedicine platform that purports to help patients access licensed providers for diagnoses, virtual care, and prescription medications. LifeMD was previously known as Conversion Labs, Inc., and its common stock traded on the NASDAQ exchange under the symbol “CVLB.” The Company’s name was changed effective February 19, 2021, and the stock symbol changed effective February 22, 2021.

On January 27, 2021, Perspecta announced its entry into an Agreement and Plan of Merger pursuant to which it would be sold to Veritas Capital.

Credit Suisse Group AG is a global financial services company.

Intrusion Inc. develops, sells, and supports products that purport to protect entities from cyberattacks by combining advanced threat intelligence with real-time artificial intelligence. It offers three products: Shield, a cybersecurity solution packaged as a comprehensive, real-time AIbased Security-as-a-Service; TraceCop, a big data tool with IP intelligence, including reputation information on known good and known bad active IP addresses; and Savant, a network monitoring solution that identifies suspicious traffic in real-time.

Franklin Wireless Corp. purports to be a leading provider of intelligent wireless solutions such as mobile hotspots, routers, trackers, and other devices.

On October 5, 2020, RMG Acquisition Corp. (“RMG”) announced a definitive agreement for a business combination with Romeo Power Inc. that would result in Romeo becoming a publicly listed company. On December 29, 2020, Romeo announced that it completed its business combination with RMG.

Canaan Inc. engages in the research, design, and sale of integrated circuit (“IC”) final system products by integrating IC products for bitcoin mining and related components primarily in the PRC.

Fibrogen, Inc. is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (“HIF-PH”) activity that acts by stimulating the body’s natural pathway for red cell production. In 2019, the Company filed its New Drug Application (“NDA”) with the U.S. Food and Drug Administration for the approval of roxadustat for the treatment of anemia due to chronic kidney disease (“CKD”).

Champignon Brands Inc. purports to be engaged in the formulation and manufacturing of novel ketamine, ketamine derivatives and other psychedelics, and delivery platforms for nutraceutical and psychedelic medicine while being supported by its psychedelic medicine clinic platform.

Amdocs Limited, through its global subsidiaries, provides software and services to communications, cable and satellite, entertainment, and media industry service providers worldwide. Historically, the Company’s largest percentage of revenues come from its North American business, mostly the U.S., particularly from large customers including, among others, AT&T Inc.

3D Systems Corp. provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on demand manufacturing services, and digital design tools.

According to the Complaint, MoneyGram International, Inc., together with its subsidiaries, is a money transfer company that allows customers to send money around the globe.

FLIR Systems, Inc. is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications.

Ebang International Holdings Inc. purports to be a leading ASIC chip design company and a leading manufacturer of Bitcoin mining machines.

Cubic Corporation is a technology-driven, marketleading provider of integrated solutions that increase situational understanding for transportation, defense command, control, communications, computers, intelligence, surveillance, and reconnaissance (“C4ISR”), and training customers worldwide to decrease urban congestion and improve the militaries’ effectiveness and operational readiness.

Kadmon Holdings, Inc. is a biopharmaceutical company that discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The Company’s lead product candidates include, among others, belumosudil (KD025), an orally administered selective inhibitor of ROCK2, which is in Phase II clinical development for the treatment of cGVHD.

Canoo Inc. (formerly known as Hennessy Capital Acquisition Corp. IV) was formed for the purpose of effecting a business combination with specific focus on businesses in the industrial, technology and infrastructure sectors. Such companies are referred to as “blank check” companies or special purpose acquisition companies (“SPACs”). In December 2020, the Company entered into a business combination with Canoo Holdings Limited. The combined company purports to be a mobility technology company that develops electric vehicles.